Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eperisone is a centrally acting skeletal muscle relaxant and antispasmodic agent. It works by relaxing both skeletal muscles and vascular smooth muscles, leading to reduced myotonia (muscle stiffness), improved circulation, and suppression of the pain reflex. Eperisone inhibits the vicious cycle of myotonia by decreasing pain, ischemia, and hypertonia in skeletal muscles. This alleviates stiffness and spasticity while facilitating muscle movement without significantly reducing muscle power or causing strong sedation compared to other antispasmodics. It is also used to improve dizziness and tinnitus associated with cerebrovascular disorders or cervical spondylosis. The drug is commonly used in rehabilitation settings for conditions such as spastic paralysis due to cerebrovascular disease or spinal cord injury, cervical spondylosis, postoperative sequelae (including after brain or spinal tumor surgery), trauma sequelae (spinal/head injury), amyotrophic lateral sclerosis (ALS), cerebral palsy, spinocerebellar degeneration, spinal vascular diseases and other encephalomyelopathies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eperisone.